Latest News on IDXX

Financial News Based On Company


Advertisement
Advertisement

IDEXX Laboratories, Inc. (IDXX) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4071_QuantitativeReport_1794960000000
Argus has lowered its target price for IDEXX Laboratories, Inc. (IDXX) to $759.00 from its current price of $689.65. The report, published on November 18, 2026, focuses on IDXX, a company that develops, manufactures, and distributes diagnostic products and services for pets and livestock within the healthcare sector.

IDEXX Laboratories Executive Chair Jonathan Jay Mazelsky Gifts 700 Shares on November 16, 2026

https://kalkinemedia.com/us/news/announcements/idexx-laboratories-executive-chair-jonathan-jay-mazelsky-gifts-700-shares-on-november-16-2026
Jonathan Jay Mazelsky, Executive Chair at IDEXX Laboratories (NASDAQ:IDXX), gifted 700 shares of common stock on November 16, 2026, as disclosed in a Form 4 filing. The transaction, categorized as a "G" for gift, involved a price of $0 per share, leaving Mazelsky with 83,103.302 direct beneficial shares. No derivative securities or indirect ownership interests were reported in the filing.

On Nov. 16, the executive chair of IDEXX Laboratories (IDXX) gave 700 common shares as a gift.

https://www.stocktitan.net/sec-filings/IDXX/form-4-idexx-laboratories-inc-de-insider-trading-activity-a54577024666.html
Jonathan Jay Mazelsky, the Executive Chair of IDEXX Laboratories (IDXX), gifted 700 common shares on November 16, 2026. This bona fide gift transaction was reported as a direct ownership transfer, leaving Mazelsky with 83,103 common shares directly held after the transaction. The transaction was filed as a Form 4 with the SEC.

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/idexx-laboratories-inc-stock-outperforms-competitors-on-strong-trading-day-66899f12-606f701d2dbf?mod=goog_fin_scmw
IDEXX Laboratories Inc. (IDXX) shares rallied 1.19% to $698.47 on Wednesday, outperforming the broader market which saw declines in the S&P 500 and Dow Jones Industrial Average. This rise broke a two-day losing streak for the company's stock.

Here's How Much $100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth Today

https://www.benzinga.com/news/26/11/63390075/here-s-how-much-100-invested-idexx-laboratories-20-years-ago-would-be-worth-today
IDEXX Laboratories (NASDAQ: IDXX) has significantly outperformed the market over the past two decades, with an average annual return of 11.1%. An initial investment of $100 made 20 years ago would now be worth $819.20. This illustrates the substantial impact of compounded returns on investment growth over time.
Advertisement

Should You Continue to Hold Charles River Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:fac182df8094b:0-should-you-continue-to-hold-charles-river-stock-in-your-portfolio/
Charles River Laboratories International (CRL) is experiencing improving demand, bookings, and backlog in its Discovery and Safety Assessment (DSA) segment, along with a strong solvency position, which supports its growth. However, the company faces competitive pressures and unfavorable foreign exchange rates that could impact its performance. The article recommends a "Hold" rating for CRL stock due to these mixed factors.

Should You Continue to Hold Medtronic Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:620995965094b:0-should-you-continue-to-hold-medtronic-stock-in-your-portfolio/
Medtronic (MDT) is positioned for growth in its MedSurg and Neuroscience segments, driven by advancements like Hugo adoption, digital surgery, and new product launches, particularly in international markets. However, the company faces headwinds from macroeconomic pressures, product mix shifts, and foreign exchange fluctuations. Despite these challenges, Medtronic has consistently surpassed earnings estimates and maintains a positive outlook for fiscal 2027.

3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance

https://www.tradingview.com/news/zacks:f510a4c86094b:0-3-stocks-rallying-after-strong-q3-earnings-and-raised-guidance/
Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all reported strong Q3 earnings and raised their guidance, leading to favorable post-earnings reactions. These companies have also shown relative strength against the broader market amidst recent volatility. Each company highlighted specific growth drivers, such as Hasbro's Wizards of the Coast segment, IDEXX's Companion Animal Group Diagnostics, and TG Therapeutics' BRIUMVI treatment.

IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors

https://www.marketwatch.com/data-news/idexx-laboratories-inc-stock-underperforms-tuesday-when-compared-to-competitors-f6368283-59a83c6b16a1?mod=goog_fin_scmw
IDEXX Laboratories Inc. (IDXX) stock fell 1.49% on Tuesday, closing at $690.24, marking its second consecutive day of losses. This underperformance occurred during a generally dismal trading session, with the S&P 500 Index declining 1.03% and the Dow Jones Industrial Average falling 1.64%.

Should You Continue to Hold ALGN Stock in Your Portfolio?

https://au.finance.yahoo.com/news/continue-hold-algn-stock-portfolio-135200507.html
Align Technology (ALGN) is expanding its Invisalign portfolio and increasing digital dentistry adoption through strategic alliances, contributing to a 25.4% stock gain over the past year. However, the company faces risks from currency volatility and competitive pressure from traditional and lower-priced clear aligner alternatives. Despite these challenges, analysts project an 8.4% long-term earnings growth rate for ALGN.
Advertisement

VolitionRx expands Japan deal with Fujifilm to cover feline cancer test

https://www.streetinsider.com/Corporate+News/VolitionRx+expands+Japan+deal+with+Fujifilm+to+cover+feline+cancer+test/27355314.html
VolitionRx Limited has expanded its agreement with Fujifilm Vet Systems Co. Ltd in Japan to develop and use a blood-based cancer screening test for cats, the Nu.Q Vet Feline Test. This builds on their existing collaboration which saw the launch of a similar canine test. The feline test aims to be the first simple, affordable liquid biopsy for feline cancer, targeting Japan's estimated nine million cats, with no timeline or financial terms disclosed.

FTC plans to sue to block Covetrus's $3.5 billion merger with Cencora's MWI Animal Health, Semafor reports

https://mlq.ai/news/ftc-plans-to-sue-to-block-covetruss-35-billion-merger-with-cencoras-mwi-animal-health-semafor-reports/
The Federal Trade Commission (FTC) is reportedly planning to sue to block the $3.5 billion merger between Covetrus and Cencora's MWI Animal Health unit. The FTC intends to argue that the deal would increase costs for pet owners and veterinary clinics and lead to a highly concentrated market, as both companies are major national suppliers of veterinary medical supplies. Cencora stands to receive $1.25 billion in cash and equity in Covetrus's parent company, totaling about 34.3% of the combined entity.

Should You Continue to Retain Bruker Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:ca498d136094b:0-should-you-continue-to-retain-bruker-stock-in-your-portfolio/
Bruker Corporation (BRKR) is positioned for growth due to strong performance in its Biosystems and Diagnostics businesses, preclinical imaging expansion, and progress toward a $140 million cost-savings target. Despite these positives, uneven academic demand and macroeconomic uncertainties pose ongoing concerns for the company. The stock has outperformed the S&P 500 Composite over the past year, and analysts remain optimistic about its future earnings.

Old Dominion Freight Line, Inc. (ODFL) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/ODFL/
This article provides detailed financial information and performance data for Old Dominion Freight Line, Inc. (ODFL), a less-than-truckload motor carrier. It covers stock price, key metrics like market cap and P/E ratio, dividend announcements, and analyst ratings. The company overview highlights its services, fleet size, and headquarters in Thomasville, North Carolina.

30 Newly Overvalued Stocks This Week

https://www.morningstar.com/stocks/30-newly-overvalued-stocks-this-week-2
Morningstar has identified 30 US-listed stocks that became newly overvalued in the past week, receiving 1- or 2-star ratings. Key companies like Berkshire Hathaway and BNY Mellon are among those now rated as expensive, with their prices climbing significantly above their fair value estimates. The article details the metrics for the top five new 2-star and 1-star stocks, explaining Morningstar's rating methodology which considers price, fair value estimate, and Uncertainty Rating.
Advertisement

Should You Continue to Hold TMO Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:4bf9b0a5b094b:0-should-you-continue-to-hold-tmo-stock-in-your-portfolio/
Thermo Fisher Scientific Inc. (TMO) is positioned for growth due to strong demand in pharma, biotech, and industrial markets, along with improving organic revenues. The company's bioproduction business is benefiting from biologics demand and expanded manufacturing capabilities, and it has actively managed debt and repurchased shares. However, macroeconomic challenges and intense competition could impact its performance.

Pet health spending remains ‘nonnegotiable’ priority, survey finds

https://www.veterinarypracticenews.com/pet-health-spending-remains-nonnegotiable-priority-survey-finds/
A recent Elanco survey indicates that pet owners consider animal health spending a non-negotiable priority, even amid economic pressures, with 93% maintaining or increasing their spending. While medication purchases are shifting away from veterinary clinics to other retail channels, veterinarians' recommendations remain the primary influence on product selection. Future demand for pet ownership also appears strong, with 25% of current owners planning to adopt another pet within the next year.

Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus

https://www.tradingview.com/news/seekingalpha:f0fa8f444094b:0-notable-healthcare-headlines-for-the-week-moderna-pfizer-and-cvs-health-in-focus/
This article summarizes the past week's notable healthcare headlines, focusing on Moderna, Pfizer, and CVS Health. Moderna saw a significant rise due to strong Q3 overseas COVID-19 vaccine sales and a raised full-year outlook. CVS Health experienced a drop despite beating Q3 expectations, as plans to split the company into two independent entities overshadowed positive financial results. Pfizer hiked its 2026 outlook after better-than-expected Q3 financials and announced a new CFO, while Novartis slipped due to safety concerns related to its gene therapy, Zolgensma.

Executive VP and GM Global Reference Laboratories Michael Lane Sold A Bunch Of Shares In IDEXX Laboratories

https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/executive-vp-and-gm-global-reference-laboratories-michael-la
Michael Lane, Executive VP and GM Global Reference Laboratories at IDEXX Laboratories, recently sold US$2.7m worth of shares, reducing his total holding by 48%. While this is a significant sale, the transaction occurred around the current share price, making it less concerning than sales at lower prices. Despite the insider selling, IDEXX Laboratories shows high insider ownership (0.3%) and is profitable and growing, though the selling activity suggests caution.

Align Technology, Inc. (ALGN) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/ALGN/
Align Technology, Inc. (ALGN) is a medical instruments and supplies company providing Invisalign clear aligners and iTero intraoral scanners. The article provides a detailed overview of ALGN's stock performance, key financial metrics, earnings trends, and analyst insights. It also includes company details, recent news, and comparative performance against the S&P 500.
Advertisement

IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/IDXX/latest-news/
This page provides an overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, recent news headlines, and performance data. The stock is trading at $685.98, up 1.47%, and the news section features articles discussing Q3 earnings, analyst ratings, and moving average performance. The performance overview compares IDXX's trailing total returns against the S&P 500 benchmark.

IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/IDXX/latest-news/
This page provides an overview of IDEXX Laboratories, Inc. (IDXX) stock, including its real-time price, news, and historical performance data. The stock closed at $676.04 on November 6 and has seen several news updates regarding its Q3 earnings and analyst ratings. Performance metrics show year-to-date and 1-year returns are negative, while the 3-year return is positive but trails the S&P 500.

IDEXX Laboratories, Inc. (IDXX) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/IDXX/seasonality/
The article provides a seasonal returns chart for IDEXX Laboratories, Inc. (IDXX), displaying the average monthly price return from 2016 to 2026. It includes current stock information, showing IDXX at $676.04, up 0.79% at market close. The page features various financial data points and market summaries.

IDEXX Laboratories, Inc. Just Beat EPS By 9.0%: Here's What Analysts Think Will Happen Next

https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/idexx-laboratories-inc-just-beat-eps-by-90-heres-what-analys
IDEXX Laboratories (NASDAQ:IDXX) recently reported quarterly results, with revenues of US$1.2 billion and statutory earnings per share (EPS) of US$4.01, beating analyst expectations by 9.0%. Analysts are forecasting revenues of US$5.17 billion in 2027, an 11% increase, and EPS to climb 11% to US$16.66. Despite the strong performance, the consensus price target remains largely unchanged at US$709, indicating that analysts' long-term views on the business prospects have not significantly shifted.

October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority

https://investingnews.com/october-consumer-research-confirms-pet-health-remains-non-negotiable-household-priority/
Elanco Animal Health Incorporated (NYSE: ELAN) released findings from its latest U.S. consumer research, indicating that pet owners prioritize pet health spending despite economic pressures, with 93% maintaining or increasing spending in the last three months. The survey also revealed a shift in pet medication purchasing towards omnichannel convenience, while veterinarians remain the primary trusted authority. Additionally, the research suggests strong future demand for pet adoption.
Advertisement

Executive Vice President At IDEXX Laboratories Sells $2.74M Of Stock

https://www.benzinga.com/news/26/11/62982290/executive-vice-president-idexx-laboratories-sells-2-74m-stock
Michael Lane, Executive Vice President at IDEXX Laboratories (NASDAQ: IDXX), sold 3,978 shares of the company's stock for a total of $2,740,069, according to an SEC filing on November 5. The article also provides a financial overview of IDEXX Laboratories, highlighting its revenue growth, gross margin, EPS, debt management, and valuation metrics, noting its premium pricing and strong market position. Insider transactions, while not sole investment determinants, offer insights into executive sentiment.

Board Member At IDEXX Laboratories Sells $844K Of Stock

https://www.benzinga.com/news/26/11/62982294/board-member-idexx-laboratories-sells-844k-stock
A board member at IDEXX Laboratories (NASDAQ: IDXX), Daniel M Junius, sold 1,200 shares of the company's stock for a total of $844,888, as reported in an SEC filing on November 5. The article also provides a financial overview of IDEXX Laboratories, highlighting its revenue growth, gross margin, EPS, debt management, and various valuation metrics. Insider transactions are discussed as an important factor, though not the sole one, in investment decisions.

Elanco Animal Health Reports Soon: How Has The Stock Reacted To Past Earnings?

https://www.trefis.com/stock/elan/articles/622775/elanco-animal-health-reports-soon-how-has-the-stock-reacted-to-past-earnings/2026-11-05
Elanco Animal Health (NYSE:ELAN) is set to release its earnings on November 6, 2026. This article analyzes the company's stock performance following past earnings reports, noting that positive one-day returns occurred 63% of the time over the last five years, rising to 75% in the last three years. It also examines correlations between one-day, five-day, and twenty-one-day post-earnings returns and considers how the earnings reactions of peers like Merck, IDEXX Laboratories, and Neogen might foreshadow Elanco's performance.

[IDEXX Laboratories Q3 2026 Earnings Call] IDEXX Raises Full-Year Revenue Guidance to $4.74–$4.77 Billion as Organic Growth Hits 10% Despite Declining Vet Visits

https://finance.biggo.com/news/US_IDXX_2026-11-02
IDEXX Laboratories reported strong Q3 2026 results, with organic revenue growth of 10% and EPS up 18%, despite a 1.8% decline in U.S. vet visits. The company raised its full-year revenue guidance to $4.74–$4.77 billion and EPS guidance to $14.96–$15.16, driven by volume-led growth from innovation, commercial execution, and high-quality vet visits. Key drivers included record instrument placements, the expansion of the Cancer Dx panel, and the acquisition of AI-native clinical workflow provider CoVet.

Form 144 IDEXX LABORATORIES INC /DE For: 5 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-idexx-laboratories-inc-de-for-5-november-93CH-4961327
This article reports on the filing of Form 144 by IDEXX LABORATORIES INC /DE for transactions made on November 5th. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and date of the filing, noting IDEXX LABORATORIES INC's stock performance.
Advertisement

An IRA sale of 500 shares is proposed by IDEXX (IDXX) director Daniel M. Junius.

https://www.stocktitan.net/sec-filings/IDXX/144-idexx-laboratories-inc-de-sec-filing-210a76c97f32.html
IDEXX Laboratories Inc. director Daniel M. Junius has proposed selling 500 common shares from his IRA, with an aggregate market value of $345,835. The approximate sale date is listed as November 4, 2026, and Fidelity Brokerage Services LLC is named as the broker. The shares were originally acquired through an open-market purchase on August 3, 2015.

Ciena (NYSE:CIEN) Clears All Eight Growth Filters With Accelerating Earnings and Cash Flow

https://www.chartmill.com/news/CIEN/Chartmill-57724-Ciena-NYSECIEN-Clears-All-Eight-Growth-Filters-With-Accelerating-Earnings-and-Cash-Flow
Ciena (NYSE:CIEN) has successfully passed all eight growth filters derived from Louis Navellier's "Little Book That Makes You Rich" strategy, indicating strong fundamental momentum. The company shows positive EPS revisions, consistent earnings surprises, accelerating sales and EPS, robust free cash flow growth, and high return on equity. While growth and balance sheet health are excellent, the article notes watch items related to average profitability and high valuation multiples.

IDEXX Laboratories, Inc. (IDXX) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/IDXX/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for IDEXX Laboratories, Inc. (IDXX), showing the average monthly price return from 2016 to 2026. It also includes the company's current stock price, recent performance, and links to various financial data sections like news, statistics, and historical data.

Danaher (DHR), Why Is It Drawing Fresh Attention Today?

https://sg.finance.yahoo.com/news/danaher-dhr-why-drawing-fresh-101407461.html
Danaher (DHR) is gaining attention due to U.S. regulatory clearance of its Access MeMed BV assay, a rapid test for distinguishing bacterial from viral infections. This approval follows strong third-quarter results and positive share price momentum, with the stock showing significant returns over 30 and 90 days. While one narrative suggests Danaher is undervalued with a fair value of $259.90, another perspective based on P/E multiples indicates the shares are trading at a premium compared to sector averages.

IDEXX Laboratories, Inc. (IDXX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IDXX/seasonality/
The article provides a seasonal returns chart for IDEXX Laboratories, Inc. (IDXX), showing the average monthly price return from 2016 to 2026. It also includes current stock performance, market data, and a replay link for the Q3 2026 earnings call.
Advertisement

Copart, Inc. (CPRT) Stock forecasts

https://sg.finance.yahoo.com/research/reports/MS_0P000001HI_AnalystReport_1793665368000
Copart, Inc. (CPRT) is an online salvage-vehicle auction operator with global operations. The company is looking to make acquisitions in both salvage and traditional auctions. Morningstar analyst David Whiston provides an overview of Copart, highlighting its business model and current market position.

6 Green Days In A Row: General Motors Stock Is Up 19%

https://www.trefis.com/stock/gm/articles/622156/6-green-days-in-a-row-general-motors-stock-is-up-19/2026-11-03
General Motors (GM) stock has experienced a significant 6-day winning streak, increasing its market value by $12.2 billion to $78.4 billion. This surge, however, appears to be stock-specific as the broader S&P 500 declined during the same period. Despite the impressive price performance, the article notes that GM's fundamentals, including declining revenue and below-median operating margins, make the run difficult to justify.

Is Procter & Gamble Stock Overvalued?

https://www.trefis.com/stock/pg/articles/622135/is-procter-gamble-stock-overvalued/2026-11-03
Procter & Gamble (PG) stock appears expensive, trading at 23.2 times its adjusted earnings despite a sales growth of only 3.5%. The valuation depends on the company's ability to meet profit forecasts for fiscal 2027 and 2028, which require continued sales growth and wider net margins. However, rising commodity costs due to Middle East conflicts and potential slowdowns in certain product categories like Pampers in Greater China could jeopardize these margin targets.

IDEXX Laboratories Inc | 8-K: IDEXX Laboratories Announces Third Quarter Results

https://www.moomoo.com/news/notice/1003182966/idexx-laboratories-announces-third-quarter-results
IDEXX Laboratories announced its third-quarter results, detailed in an 8-K filing. This release provides key financial and operational performance data for the quarter, offering transparency to investors and the market.

Monster Beverage Corporation (MNST) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/MS_0P000002L4_AnalystReport_1793603960000
Morningstar released an analyst report on Monster Beverage Corporation (MNST), highlighting its leadership in the energy drink category. The report emphasizes Monster's strategy of supporting its brand and driving growth through innovation and limited-time offerings, with two-thirds of its revenue generated in the US and Canada. The company's well-known trademark includes popular brands such as Monster Energy, Monster Ultra, Java Monster, and Juice.
Advertisement

Crawford & Co Q3 Results: Adjusted EPS $0.37 beats estimate, sales miss

https://scanx.trade/stock-market-news/companies/crawford-co-q3-results-adjusted-eps-0-37-beats-estimate-sales-miss/55200496
Crawford & Co reported third-quarter adjusted earnings per share of $0.37, beating analyst estimates by 19.35%, and representing a 15.62% increase year-over-year. However, the company's sales of $321.6 million missed consensus estimates by 2.96%, with revenue showing a marginal 0.19% decline compared to the prior year. This divergence suggests that profitability improvement was driven by operational efficiency or cost management rather than top-line growth.

12 Health Care Stocks Moving In Monday's Intraday Session

https://www.benzinga.com/trading-ideas/movers/26/11/62787056/12-health-care-stocks-moving-monday-s-intraday-session
This article details the top gainers and losers among healthcare stocks during Monday's intraday session. Inovio Pharmaceuticals led the gainers with a significant surge of 211.2%, while Karyopharm Therapeutics experienced the steepest decline, falling by 83.5%. The report provides stock movements, market caps, and brief reasons for some notable changes, such as IDEXX Laboratories' increase following its Q3 earnings report.

Crown Holdings stock reaches 52-week high at $122.97

https://www.investing.com/news/company-news/crown-holdings-stock-reaches-52week-high-at-12297-93CH-4992642
Crown Holdings Inc. (CCK) stock has reached a 52-week high of $122.97, reflecting positive investor sentiment and a 26.16% increase over the past year. InvestingPro analysis suggests the stock is currently undervalued despite its strong financial health. The company also reported strong third-quarter 2026 results, surpassing earnings and revenue expectations due to increased global can shipments, though inflation and geopolitical costs remain concerns.

IDEXX Laboratories Releases Q3 2026 Financial Results

https://news.alphastreet.com/idexx-laboratories-releases-q3-2026-financial-results/amp/
IDEXX Laboratories reported strong Q3 2026 financial results, with comparable earnings per share of $3.96, surpassing analyst estimates. The company achieved $1.21 billion in revenue, a 10.0% increase year-over-year, driven by its Companion Animal Group and continued demand for diagnostic testing platforms. Management provided full-year 2026 EPS guidance between $14.96 and $15.16, anticipating continued growth in pet healthcare spending.

Idexx Labs Earnings: Stellar Quarterly Performance Leads to Bump in Management Outlook

https://www.morningstar.com/company-reports/1507190-idexx-labs-earnings-stellar-quarterly-performance-leads-to-bump-in-management-outlook
Idexx Labs reported strong third-quarter results, with top-line and bottom-line year-over-year growth of 10% and 16% respectively. This performance was driven by double-digit increases in VetLab consumables and reference lab revenue. Following the announcement, Idexx shares saw a 20% increase.
Advertisement

IDEXX Laboratories surges 22% on Q3 beat, raised outlook (IDXX:NASDAQ)

https://seekingalpha.com/news/4662829-idexx-laboratories-surges-22-on-q3-beat-raised-outlook
IDEXX Laboratories (IDXX) shares surged nearly 22% after the company reported better-than-expected third-quarter results. The veterinary diagnostics manufacturer also raised its full-year outlook, contributing to the strong investor reaction. The article highlights the significant market response to IDEXX's positive financial performance.

Tetra Technologies Q3 Results: Adjusted EPS $0.06 beats estimate

https://scanx.trade/stock-market-news/companies/tetra-technologies-q3-results-adjusted-eps-0-06-beats-estimate/55205091
Tetra Technologies reported strong Q3 FY26 results, with revenue reaching a ten-year high of $167.951 million, exceeding estimates by 7.07%. The company's adjusted EPS of $0.06 beat consensus estimates by 50%, driven by robust performance in Completion Fluids & Products, Water & Flowback Services, and international growth. Despite overall margin pressures, strategic developments like the Arkansas bromine plant and an amended credit agreement position Tetra for continued growth in 2027.

Ameresco raises FY26 adj EPS guidance to $1.15-$1.35, beats est

https://scanx.trade/stock-market-news/companies/ameresco-q2-results-revenue-rises-9-to-515-46-million/47337569
Ameresco Inc. has increased its full-year 2026 adjusted EPS guidance to $1.15-$1.35, exceeding analyst estimates, while maintaining its revenue guidance of $2.0-$2.2 billion. This revision follows a Q2 2026 revenue growth of 9.14% to $515.46 million, driven significantly by data center demand, and despite a decline in adjusted EPS for the quarter. The company's record backlog of $6.73 billion and recent $1.8 billion in new awards, including $1.2 billion for data centers, underpin management's confidence in future margin expansion.

UNITIL earnings beat by $0.68, revenue fell short of estimates

https://www.investing.com/news/earnings/unitil-earnings-beat-by-068-revenue-fell-short-of-estimates-4993000
UNITIL (NYSE: UTL) reported third-quarter earnings per share of $0.62, significantly beating analyst estimates of $-0.06. However, the company's revenue of $88.5 million fell short of the consensus estimate of $117.49 million. Despite the revenue miss, UNITIL's stock has seen positive performance, rising 4.91% in the last three months and 14.95% over the past year.

IDEXX Laboratories 3Q 2026: Revenue $1.21B, Net income $317.15M, EPS $4.01— 10-Q Summary

https://www.tradingview.com/news/tradingview:27fef8a195e6e:0-idexx-laboratories-3q-2026-revenue-1-21b-net-income-317-15m-eps-4-01-10-q-summary/
IDEXX Laboratories reported strong financial results for the third quarter of 2026, with revenue increasing 9.9% year over year to $1.21 billion. Net income rose 15.5% to $317.15 million, and diluted EPS grew 17.9% to $4.01. The growth was primarily driven by companion animal diagnostics recurring revenue, supported by higher testing volumes and expanded test menus.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement